- Home
- ICLR
ICLR
ICON plc
as 10-24-2025 3:50pm EST
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
| Founded: | 1990 | Country: | Ireland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 14.3B | IPO Year: | 1998 |
| Target Price: | $211.36 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.47 | EPS Growth: | -16.84 |
| 52 Week Low/High: | $125.10 - $242.72 | Next Earning Date: | 10-22-2025 |
| Revenue: | $8,102,602,000 | Revenue Growth: | -2.46% |
| Revenue Growth (this year): | -1.75% | Revenue Growth (next year): | 1.68% |
Latest ICON plc News
ICLR Breaking Stock News: Dive into ICLR Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
ICON Reports Third Quarter 2025 Results
Simply Wall St.
24 days ago
Is It Time To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Insider Monkey
a month ago
Jefferies Downgrades ICON Public Limited (ICLR) to Hold From Buy
Simply Wall St.
2 months ago
ICON (ICLR) Valuation in Focus Following CEO Transition and Stable Guidance
Business Wire
2 months ago
ICON Announces CEO Transition
Simply Wall St.
2 months ago
ICON’s Interim Financials Prompt Fresh Questions About Operational Agility and Efficiency for ICLR Investors
Insider Monkey
2 months ago
Mizuho Raises PT on ICON Public Limited Company (ICLR) to $225; Maintains ‘Outperform’ Rating
Insider Monkey
2 months ago
ICON (ICLR) Fell Along with Broader CROs
Compare ICLR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ICLR ICON plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.